COMPASS Pathways stock
CMPSNASDAQCOMPASS Pathways plc, HealthcareISIN US20451W1018
35Score 35 out of 100, Weak
Price and trend
47 / 100
Price history
+56% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 13% below it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 40% below its 52-week high. Largest decline in 6 years: 96% (December 2020 to June 2025).
Chart figures for advanced users
- SMA 50$11.98
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.94
- The lowest closing price of the last twelve months.
- Resistance$15.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- COMPASS Pathways plc belongs to the Biotechnology industry (United Kingdom) and, with a market value of $1.28B, is number 169 of 289 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- MEQIRI Score 35 out of 100 (Weak): rank 606 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $149.61M, financial debt $20.93M.
Weaknesses
- DilutionShare count up 160% since 2020.Capital allocation 24
- Loss-makingLoss of $287.86M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 93% a year over the last 12 months.Stability 46
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Mar 2027in 130 days
- Last reported
- 3 Nov 2026above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 19.1% since 15 Oct 2026.
- Earnings per share
- −1.82+19.1%
- Revenue
- $2M0.0%
- Earnings per share
- −1.6+3.5%
- Revenue
- $30.68M−6.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +14.8%Timeline unchanged: the NDA submission is still expected in the fourth quarter.
“With the final submission of our NDA expected in the fourth quarter, our focus in the second half of this year is on operationalizing launch plans and ensuring launch readiness.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at COMPASS Pathways
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Pharma MarPHM.MC $1.31B59
- OmerosOMER $1.3B52
- UroGen PharmaURGN $1.29B36
- Inhibrx BiosciencesINBX $1.29B33
- IdorsiaIDIA.SW $1.28B35
- Nektar TherapeuticsNKTR $1.27B29
- GH ResearchGHRS $1.27B36
- KardiganKARD $1.26B44
ETFs that hold COMPASS Pathways
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 0.71% | 0.49% | €318.64M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.07% | 0.35% | €1.25B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.